Amgen Inc. said its earnings increased in the third quarter, driven by strong growth of key drugs such as cancer therapy Kyprolis. "Amgen Posts Strong Results on Higher Sales--Update" published at 5:39 p.m. and an earlier version at 4:01 p.m. misspelled the name of drug as Krypolis in the lead of the story.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amgen Charts.